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Abstract: The use of health technology assessment (HTA) to inform policy-making is 
established in most developed countries. Compared to licensing agencies, HTA agencies 
have different interests and, therefore, different evidence requirements. Criteria for coverage 
or reimbursement decisions on pharmaceutical compounds vary; however, it is common to 
include, as part of the HTA, a comparative effectiveness evaluation. This type of clinical data 
might go beyond that required for market authorization, thus creating an additional evidence 
gap between the regulatory and the reimbursement submission. The relevance of submissions 
to HTA agencies is consistently increasing in a pharmaceutical company’s perspective, as 
market prospects are strongly influenced by third-party payers’ coverage. In this study, we aim 
to describe current HTA activities with a potential impact throughout the drug development 
process of pharmaceuticals, with a comparative emphasis on the systems in place in Italy and in 
the UK. Based on an extensive literature and website review, we identified three major classes 
of HTA activities, beyond mainstream HTA, with the potential to influence the drug develop-
ment program: 1) horizon scanning and early HTA; 2) bipartite and tripartite early dialogue 
between manufacturers, regulators, and HTA assessors; and 3) managed market entry agreements. 
From early stages of clinical research up to postauthorization studies, there is a trend toward 
increased collaboration between parties, anticipation of market access evidence collection, 
and postmarketing risk-sharing. Heterogeneity of HTA practices increases the complexity of 
the market access environment. Overall, there are signals that market access departments are 
gaining importance in the pharmaceutical companies, but there is still a lack of evidence and 
reporting on how the increasing relevance of HTA has reshaped the way clinical development 
is designed and managed.
Keywords: health technology assessment, horizon scanning, scientific advice, risk sharing, 
drug development
Introduction
During the last decades, governments across many jurisdictions have been faced by 
the challenge of controlling increasing health care expenditure, partly due to new 
medical technologies, within a context of dwindling budgets, exacerbated by the recent 
economic and financial crisis. As a result, demand for evidence and justification of 
value are increasingly a requirement to support funding, coverage, and reimbursement 
decisions or price negotiation about health technologies.1 The use of health technology 
assessment (HTA) to inform policy-making is established in North America, Australia, 
in many European countries, and is rapidly growing in Latin America and Asia.2–6 
HTA has been described as the multidisciplinary process that summarizes information 
about several dimensions (eg, clinical, ethical, economic) related to the use of a 
health technology with the aim to achieve the best value in the allocation of public 
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resources.7 In countries where HTA is in place, third-party 
payers, pricing and reimbursement agencies, or HTA bodies 
rely upon HTA to determine the reimbursement status of a 
drug (eg, listing in the local formulary), to issue guidance 
about the appropriate use of the technology within the health 
care system, and to support the price negotiation process.8 
According to the remit of the organization and the structure 
of the health care system, this role is played at the central/
national level or regional/provincial level.9
Compared to licensing agencies that are focused on the 
risk-benefit profile of a product, evaluated in a rigorously 
controlled setting, typically randomized controlled trials, 
with high attention on internal validity, safety, efficacy, and 
manufacturing, HTA agencies have different interests and, 
therefore, different evidence requirements.10 Criteria for 
coverage or reimbursement decisions on pharmaceutical 
compounds vary across countries; however, it is common 
to include, as part of the HTA, a comparative effectiveness 
evaluation.11 Demonstrating relative effectiveness in addition 
to efficacy means providing evidence that the intervention 
has beneficial health outcomes under “real-world” condi-
tions and in comparison with the local standard of care. The 
most stringent criteria of effectiveness versus efficacy are 
often met in a subgroup of the licensed-approved popula-
tion; therefore, the HTA report has to focus on the appro-
priate target population identified from the reimbursement 
agencies’ perspective.12 In terms of health outcomes, final 
patient-relevant outcomes, which are outcomes that reflect 
how patients feel, function, or survive,13 are preferred over 
surrogate or intermediate outcomes (eg, bone mineral 
density, ejection fraction) by pricing and reimbursement 
agencies.14 This type of clinical data might go beyond that 
required for market authorization, thus creating an additional 
evidence gap between the regulatory and the reimbursement 
submission. In many cases, the information required at the 
market access stage also includes economic data, presented 
as cost-effectiveness analyses,12 budget impact analyses, or 
other types of economic evaluation.
Although submissions to HTA agencies do not have the 
same legal status as submissions to regulatory bodies, their 
relevance is consistently increasing in a pharmaceutical 
company’s perspective, as market prospects are strongly influ-
enced by third-party payers’ coverage. This is because market 
access, together with market authorization, is often regarded 
as an important goal of the drug development program,15 and 
technology appraisal is playing a significant role in opening or 
hindering market access for many innovative products.
A standard representation of the drug development 
process is given in Figure 1, where a simplified sequence 
of stages from basic research, discovery, and preclinical 
research, through clinical and postmarketing development 
is illustrated.
In order to overcome the challenges posed by the “fourth 
hurdle,”16,17 the manufacturers need to plan in advance for 
the evidence requirement and assessment for coverage and 
reimbursement. Moreover, while in the past postmarketing 
risk of failure of pharmaceuticals was sustained by payers, in 
recent years, managed market entry agreements (MMEAs) 
have been introduced. Under such agreements, the risk of a 
negative risk-benefit profile or excessive burden is, at least 
partially, covered by the industry; therefore, the drug develop-
ment cycle has to evolve to provide data for this purpose.
In this study, we aim to describe current HTA activities, 
with comparative emphasis on the systems in place in Italy 
and in the UK, with the potential to impact on the drug 
development path of pharmaceuticals.
Figure 1 Schematic representation of the drug development process with timeline, attrition rate, and sample sizes of clinical studies.
Notes: Timing of different stages and sample sizes vary according to different countries, manufacturers, and indications. Reprinted from Drug Discov Today, 17. van Nooten F, 
Holmstrom S, Green J, wiklund i, Odeyemi iA, wilcox TK. Health economics and outcomes research within drug development: chal lenges and opportunities for 
reimbursement and market access within biopharma research. 615–622. © 2012, with permission from elsevier.10
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Methods
We accessed the scientific literature as of June 2014 via 
PubMed, using two relevant keywords (ie, “HTA” and “drug 
development”), to build the background for this study. As we 
referred to institutionalized HTA activities,18 we identified 
two HTA bodies, the National Institute of Health and Care 
Excellence (NICE) in the UK19 and the Italian Drug Agency 
(AIFA [Agenzia Italiana del Farmaco]) in Italy20 and accessed 
their institutional websites to collect information according 
to a predefined template. The two agencies were selected 
because, 1) they are operating in large and dynamic pharma-
ceutical markets, 2) they have both introduced an early advice 
program on HTA with relevant guidance published on institu-
tional websites, and 3) they present different models of price 
and reimbursement. In the UK, there is no formal negotiation 
of price and reimbursement status between the agency and the 
manufacturer, which is instead indirectly regulated through 
the Pharmaceutical Price Regulation Scheme. Prioritized 
drugs are subject to an appraisal process based on clinical and 
cost-effectiveness data, managed by NICE and the Scottish 
Medicine Consortium, that produces a positive (fully or 
restricted) or negative recommendation. In Italy, price and 
reimbursement are simultaneously negotiated by AIFA and 
the pharmaceutical company: disease relevance (ie, target 
population), place in therapy, added therapeutic value, and 
drug budget impact, together with prices in other countries, 
are the most important parameters considered, whereas cost-
effectiveness does not play an important role.21
Results
The development of HTA to inform the coverage and reim-
bursement decisions about new drug therapies has necessarily 
contributed to the streamlining of the drug development 
program. In particular, the emphasis on the incremental 
socioeconomic value to be established on new medical 
technologies has fostered the adoption and relevance of 
health economics and outcomes research through the drug 
development process.10 As outlined earlier, mainstream HTA 
activities and reports demand more additional evidence than 
do regulatory dossiers. Effectiveness under “real-world” 
conditions and in comparison with the current standard of 
care, patient-relevant outcomes, patient-reported outcomes, 
and health-related quality of life, economic data, and, albeit 
with various definitions, innovation, are usually required in 
a value dossier for coverage and reimbursement agencies. In 
order to address these needs, manufacturers have strategically 
started to secure time and funding during the clinical develop-
ment program to integrate health economics and outcomes 
research endpoints in clinical studies, to develop, validate, 
and use patient-reported outcomes tools (eg, dermatology 
life quality index, psoriasis area, and severity index), to run 
burden of illness studies and build cost-effectiveness models 
or budget impact analyses.
Most importantly, on top of mainstream HTA, our review 
identified other activities, with lower levels of diffusion to 
date, that have the potential to influence the drug development 
process of a new medical technology. These are described 
in the following sections.
Horizon scanning and early HTA
Horizon scanning systems (HSSs) were introduced as part 
of the broad cycle of HTA in order to systematically assess 
the potential impact of new and emerging technologies to 
anticipate policy development, access, and provision of 
health services.22 For this reason, they are also called “early-
warning” or “early-awareness” systems.
Since 2006, the vast majority of topics for technology 
appraisals at NICE are identified by the National Institute 
for Health Research Horizon Scanning Centre, based at the 
University of Birmingham.23 Technologies are prioritized 
based on the expected health benefit or financial impact, 
inappropriate use, and variation of use across the country 
and effect on other health-related policies, such as reduction 
in health inequalities. This process allows notification of 
relevant new drugs at NICE, 20 months before the market 
authorization.
In Italy, AIFA does not have an HSS in place. In 2008, 
this institution co-founded a project, named Italian Horizon 
Scanning Project (IHSP), which is still part of the European 
Network of Horizon Scanning (HS) Centres.24 The IHSP 
produces an annual list of drugs that are expected to be 
launched within 3 years; every 6 months, a report on the 
epidemiology of the target population, the clinical evidence, 
and the comparators of listed drugs is released and a more 
detailed report on prioritized drugs is released 12 months 
before their expected market launch. Prioritization depends 
on the burden of disease, the therapeutic value, and the 
expected impact on drugs expenditure. Despite the fact that 
AIFA has co-founded IHSP, there is no evidence on whether 
and how it has relied on the results of this project.
Murphy et al25 described an effective HSS as one that 
identifies innovations likely to have a significant impact 
and disseminates in a timely manner the information 
relevant to the needs of the customers, so as to enable 
appropriate decision making, facilitate appropriate adop-
tion, and identify further research requirements. These 
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characteristics are summarized in a set of five primary (ie, 
relevance of information, independence, sufficient staff 
and funds, clearly defined pathway for the outputs to reach 
decision-makers, and defined customers) and eleven sec-
ondary indicators (eg, international collaboration, centrally 
coordinated, where tasks can be distributed among the 
participants, collaboration with industry to obtain informa-
tion). They were used to assess the 12 European Network 
of HS Centres member agencies,26 with some degree of 
variability in the presence of these desirable features. 
According to the definition, HSSs are primarily intended 
to support governments and health authorities’ decision-
making and planning to anticipate the impact of emerging 
technologies within the health care system. However, HSSs 
may also contribute to support key decisions made by the 
manufacturers during the product development process. 
Although experiences have been reported mainly on diag-
nostics and devices,27–29 HSSs may help the drug developers 
to anticipate possible barriers to the downstream market 
access decision and to proactively work to overcome those 
by shaping the market and engaging stakeholders and key 
opinion leaders.
Ijzerman and Steuten30 proposed a conceptual framework 
for “early HTA” as a tool to inform mainly the industry. 
Early HTA is identified as the early assessment of safety, 
effectiveness, and cost-effectiveness profiles of new medical 
technologies based on evidence mainly derived from bench 
and animal tests, early clinical experience, and previous gen-
erations of the technology.31 This tool is certainly more suit-
able for the evaluation of medical devices than drugs32 and the 
extent to which it influences product development decisions 
is to date not known. Moreover, although its denomination 
seems to fall under the broad HTA umbrella definition, it 
is rarely used by HTA bodies and it is being developed by 
consultants or manufacturers to support industry and inves-
tors’ decisions on design and management of the technology, 
regulatory, and reimbursement strategies.30
Bipartite and tripartite scientific 
advice
Some reimbursement agencies have set up in recent years 
early scientific advice (SA) services to pharmaceutical 
companies in order to outline, for specific submissions, the 
expected evidence base that could lead to optimal market 
access outcomes.
NICE was the first agency to set up HTA product-
specific SA in 2009 (Table 1).33 The objective was to help 
product developers generate the evidence that is relevant 
for technology appraisal, with the aim of gaining more 
robust data for the reimbursement perspective, reducing 
the uncertainty at the time of the appraisal, and there-
fore, the length of decision-making and patients’ time to 
access the therapies. The SA services given relates with a 
broad range of issues concerning the strategic development 
plans for postregulatory evaluation rather than advice on 
regulatory requirements or a preevaluation.34 The content 
of the SA pertains to research design considerations (eg, 
study population, follow-up duration, appropriate com-
parators, endpoints, and type of study), approaches to 
economic analysis and generation of quality-adjusted life 
years, interpretation of guidelines, and other methodologi-
cal issues. As the aim is that of making an impact on the 
strategic development and evidence generation plans, it is 
recommended to seek the advice when there is still time for 
the companies to amend the design of the pivotal trials, ie, 
when Phase III study design is ongoing. At NICE, the SA is 
available as a fee-for-service consultation to manufacturers, 
and it is provided through a structured process. The com-
pany seeking advice has to contact the unit up to 9 months 
before the actual meeting and prepare a predefined briefing 
book with all relevant information for the advisors and a set 
of clearly stated questions accompanied by the respective 
manufacturer’s position on them.35 After about 12 weeks 
of indirect exchange, a 4-hour face-to-face meeting is held 
where NICE staff and companies’ representatives engage 
in a discussion around the questions on the agenda. After 
this meeting, a report is drafted and sent to the company 
for follow-up. As of October 2013, 77 SA requests from 26 
companies were recorded at NICE; of these 17 (22%) were 
withdrawn, possibly because final agreement on the contract 
between client and agency was not reached.36 Of the remain-
ing technologies, the majority (26 out of 60, 43%) were 
in the trial progression state, 17 (28%) had completed the 
trials, and only one had completed the technology appraisal 
process, gaining a positive recommendation. However, as 
Osipenko noted, HTA advice was sought for that particular 
drug when the Phase III trial design was locked, thus limit-
ing the likelihood of the favorable reimbursement decision 
being due to the HTA advice provided.36 In addition to the 
standard bipartite (ie, between HTA body and manufacturer) 
SA process, this agency also provides feedback on the drug 
development plan from the payers’ perspective alongside 
the Medicines and Healthcare Products Regulatory Agency 
and the European Medicines Agency (EMA).
In 2011, AIFA introduced both an SA and an HTA 
Advice (SA-HTA) for regulatory and HTA purposes in Italy 
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Table 1 Comparison of HTA SA at NiCe and AiFA
Agency NICE (England and Wales) AIFA (Italy)
Name of the program NiCe SA SA
Date of establishment 2009 2011
Technologies Pharmaceuticals; Device and Diagnostics Pharmaceuticals
Overview of the program NiCe SA provides fee-for-service consultation  
to pharmaceutical companies. By reviewing early  
product development plans, NiCe can advise  
companies on whether these will generate  
relevant evidence for future submissions to NiCe
AiFA SA provides fee-for-service consultation to 
pharmaceutical companies. The SA has the main purpose 
to provide scientific and methodological support on tests 
and studies, including compliance to Good Manufacturing 
Practices, on quality, safety, and efficacy. However, the SA 
may be extended to HTA issues
How long does it take? About 11 months 3 months from contract stipulation, with possible clock 
stops
Process steps Booking an advice slot Request of advice by the company through a web-based 
form
Agreement of terms, signing of the contract,  
and start of project
Answer in 20 working days by the SA Coordinator
Completion of briefing book by the company evaluation Team + fee due in 5 working days to AiFA
Clarification questions (offline) Contract stipulation
Face-to-face meeting Draft document delivered by AiFA and discussed with the 
company in 60 days
Advice report Minutes of meeting provided by the company
Follow-up and clarification evaluation report by the evaluation Team in 90 days
what advice is sought for? interpretation of appraisal methods guidance  
and its relevance for the products
For HTA issues, relative efficacy and effectiveness
Research design considerations or preferences  
to support each proposed indication
economic evaluation and design considerations  
or preferences
Methods issues
Considerations and insights from existing models
Funding Fee-for-service offered to manufacturers Fee-for-service, ranging €10k–€40k euros
what is the status of  
the advice for future  
decisions?
The advice is not legally binding and not  
indicative of what the decision of the body  
will be at the time of the appraisal
Guidelines state that “advice is prospective in nature” and 
cannot be applied for the assessment of studies included in 
the marketing authorization dossier, once they have been 
completed
is the program linked with  
the regulatory approval?  
How?
Applications for SA in parallel with the eMA and  
MHRA are possible and welcome. NiCe will  
produce separate advice documents from the  
regulators to answer the respective questions  
raised by the company
it could be
Abbreviations: eMA, european Medicines Agency; HTA, health technology assessment; MHRA, Medicines and Healthcare Products Regulatory Agency; NiCe, National 
Institute of Health and Care Excellence; AIFA, Agenzia Italiana del Farmaco; SA, Scientific Advice.
(Table 1).37 The guidelines for applicants to both processes 
were published in November 2012 and are available on the 
institutional website. As it is possible to ask for both advices 
jointly, this document refers to preclinical and clinical devel-
opment for marketing authorization and production issues. 
The HTA aspects are generally related to relative efficacy 
and relative effectiveness evaluation. The SA-HTA advice 
is generally asked for a single product in early stages of 
the product development, but it may be requested also for 
broader therapeutic classes. Issues subject to advice include 
the most appropriate comparator(s), the endpoints used, 
and the acceptability of indirect comparison. In addition, due 
to the relevance of disease severity and drug budget impact 
in price/reimbursement negotiation, the advice sought might 
often relate to the target population. Applicants wishing to 
apply should fill in a predefined form, the rationale for the 
request, whether other advices have been received by other 
European Agencies, and the specific questions asked. Within 
20 working days, the SA Coordinator notifies the applicant 
by email regarding whether the request for SA is acceptable 
or not. After 5 working days, the AIFA Evaluation Team is 
defined and the contract is drafted including the fee due to 
AIFA, which ranges from €10k to €40k, according to the 
questions asked. The answers by the Evaluation Team are 
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collected in a report due in 90 days from the signing of the 
contract between the agency and the company. A prelimi-
nary version of the report is discussed after 60 days with 
the company, within a meeting or a teleconference. The 
minutes of the meeting are expected by the company and 
should be validated by the Evaluation Team. The current 
uptake of this service by manufacturers in Italy is currently 
not publicly available. A representative of the agency reports 
that 21 advices have been processed in 2011–2013: eleven 
(52%) for cancer and autoimmune diseases, five (24%) for 
neurologic diseases, four (19%) for infectious diseases, and 
one (5%) for hormone-related therapies.38 They generally 
refer to products in Phase II (likely to be authorized after 
Phase II) and Phase III.
The so-called tripartite “early dialogue” between regula-
tors, HTA organizations, and industry is gaining attention due 
to the potential advantages attached to it. First and foremost, 
it may reduce delays to patient access as the advice for dif-
ferent data needs for regulators and HTA bodies is sought 
in parallel rather than in sequence. Second, it provides an 
opportunity to learn about HTA requirements at an early stage 
and to discuss divergent data needs with all parties around 
the same table, with the aim of minimizing discrepancies 
and identifying trade-offs.39 For instance, when discussing 
the comparator for a novel therapy for chronic obstructive 
pulmonary disease during a parallel HTA-EMA SA session, 
the regulator agreed with the proposed licensed comparator 
while the HTA agency wanted to compare the value of the 
new therapy to what it will replace in practice, even if the 
alternative was not licensed for that use. The solution agreed 
was to introduce a new arm in the pivotal study to include 
both options.40 Thirty procedures have undergone the parallel 
HTA-EMA SA process so far; of those, 23 are now final-
ized. They include drugs for several conditions: diabetes, 
Alzheimer’s disease, oncology, asthma, rheumatoid arthritis, 
osteoporosis, food allergies, and orphan conditions.40 The 
HTA advice in the tripartite early dialogue may come from 
one or more reimbursement agencies, often represented 
through the European Network for HTA (EUnetHTA).41 As 
different HTA bodies may focus on different dimensions 
(eg, relative clinical effectiveness versus cost-effectiveness), 
this multi-HTA dialogue aims at supporting the company 
in finding a balance between perspectives from licensing 
body and HTA agencies in different countries as well as its 
own international product development program.42 Most of 
the time, the HTA body involved in the EMA-HTA parallel 
SA has been NICE, followed by the German Federal Joint 
Committee (G-BA) and AIFA.43
HTA role on postmarketing 
development
Linking between licensing and market access evidence 
requirements is also being extended to the postmarketing 
phase, with the aim of creating continuum evidence genera-
tion requirements relevant for registration, reimbursement, 
and postauthorization research.44 Insufficient evidence and 
uncertainty at market launch and the need of limiting the 
budget impact of new drugs have increased the number of 
MMEAs. The taxonomy of these agreements has been illus-
trated in a recent review.45,46 MMEAs may be 1) financial 
based or outcome based, when the price, the reimbursement 
status, or both depend on the financial and clinical impact, 
respectively, and 2) population based or patient based, when 
the performance is measured on the population as an aggre-
gate or on each individual patient (Table 2). Population- and 
outcome-based agreements, sometimes called coverage 
with evidence development, generally rely on new obser-
vational studies or randomized controlled trials, whereas 
individual- and outcome-based agreements are usually based 
on registries.47
Both payers and the industry may take advantage of 
MMEAs.48 In a situation where the alternative would be not 
reaching drugs reimbursement at the price requested by the 
industry, MMEAs allow the product to be accessible to the 
patients, the companies to leave the list price in the price-
corridor defined by the headquarters, and at the same time, 
to improve their reputation by making drugs accessible and 
sharing the risk of clinical failure and financial impact with 
payers. On the other hand, payers have the advantage of 
 prioritizing drugs, collecting real-world evidence, and apply-
ing, in the case of outcome-based agreements, value-based 
price and reimbursement. The system as a whole takes the 
advantage of avoiding the risk that the drug is not available.
Outcome-based agreements are more consistent with 
value-based pricing and reimbursement, and have the poten-
tial to influence the drugs development program differently 
from financial-based agreements. However, they are more 
complex to manage. The work of a dedicated task force at 
the International Society of Pharmacoeconomics and Out-
come Research has recently disentangled important issues 
Table 2 Managed market entry contracts taxonomy
Population level Patient level
Financial based Discounts
Price/volume agreements
Capping
Discounts on first cycles
Outcome based Coverage with evidence 
development
Performance-linked 
reimbursement
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deriving from these agreements, including their desirability, 
design, governance, implementation, and impact evaluation,47 
all essential factors for a successful contract. For example, 
the coverage with evidence development contract on drugs 
for multiple sclerosis in the UK has partially failed49 due to 
important delays in patients’ recruitment and data analysis, 
and, on top of them, incompleteness of the contract.47 These 
agreements are highly desirable if the drug has an important 
budget impact (high unit price and/or volume); the level of 
uncertainty on benefits is significant, but the expected benefit 
is so high that the opportunity cost of delaying access to get 
more evidence would not be acceptable.
The English and Italian approach to MMEAs is different. 
The UK has mainly adopted a dichotomous approach at 
market launch: the drug is recommended (or recommended 
for a restricted target) or not recommended. In order to make 
accessible drugs that are not cost-effective at list price, several 
strategies are in place: 1) companies have been allowed to 
require a patient access scheme: 31 of the 44 patient access 
schemes are discounts on list prices,50 2) thresholds on incre-
mental cost-effectiveness ratio have been increased for some 
drugs categories (eg, for end-of-life treatments, indicated for 
patients with a short life expectancy – normally 24 months 
– small patient population and with sufficient evidence that 
the treatment offers an extension to life of at least 3 months, 
compared to current National Health Service treatment),51 3) a 
cancer drugs fund has been created to partially cover cancer 
drugs that have not been recommended (eg, aflibercept as a 
second-line treatment of metastatic colorectal cancer) – or are 
waiting to be appraised (eg, pertuzumab as first-line treatment 
of locally advanced or metastatic breast cancer).52
While in the UK, apart from patient access schemes, 
access is mostly driven by cost-effectiveness at market 
launch and many drugs have not been recommended, in 
Italy most of the new drugs are approved with an MMEA 
(sometimes with multiple MMEAs), and outcome-based 
contracts have been implemented, particularly on an 
 individual basis, to oncological drugs: 25 drugs have been 
subject to such contracts to date. For example, everolimus 
has been approved with a performance-linked reimbursement 
contract that requires a payback to hospitals from Novartis 
should patients not respond after 3/6 months of treatment for 
advanced renal carcinoma/human epidermal growth factor 
receptor-2–negative advanced breast cancer and primitive 
neuroectodermal tumor, respectively. Finally, registries on 
46 drugs have been created to carry out the 25 outcome-based 
contracts and, under a broader perspective, to review the 
prescribing behavior for expensive drugs.53
Discussion
This study highlights particular HTA activities that are 
spreading in most developed countries with the potential of 
significantly influencing the drug development paths of new 
pharmaceuticals. From early stages of clinical research up to 
postauthorization studies, there is a trend toward increased 
collaboration between parties,54 like regulators, developers, 
and HTA assessors, to improve the evidence profile of new 
drugs, to anticipate patients’ access to innovative therapies, 
and to reduce clinical and economic risks deriving from an 
incomplete knowledge profile at the time of the launch.44 
Comprehensiveness and inclusiveness are acknowledged in a 
new paradigm, known as constructive HTA, which, in addi-
tion to traditional HTA, emphasizes the technology dynamics 
elements and the thorough assessment and involvement of 
multiple stakeholders in the production and evaluation of 
different types of new evidence.55,56 Another emerging feature 
is the anticipation of market access evidence collection to 
early stages of development and the increasing importance 
of postmarketing real-world evidence.
It is accepted that the evidence required for marketing 
authorization and market access is different: comparative 
evidence and cost consequences are gaining importance in the 
eyes of payers, and payers are more and more important for 
market access. While licensing and regulatory postmarketing 
risk plans are quite homogeneous across regulators in different 
jurisdictions (eg, EMA, Food and Drug Administration in 
the US), payers may have different preferences on compara-
tive clinical and economic evidence, despite the effort of the 
European Network for HTA collaboration to develop common 
methodologies and practices for HTA across European mem-
ber states. Hence, the companies are offered the currently avail-
able opportunities for bipartite and tripartite early dialogue 
between regulators and HTA assessors to identify product 
development plans that satisfy both interlocutors. Companies’ 
representatives who took part in the SA process generally agree 
that the advice given is reasonable and constructive; some 
declare to have modified the development program as a result 
of the consultation.15,36,57 However, based on the current avail-
able experience and poor reporting of it, it is generally difficult 
to establish whether the modification and which modification 
on the drug development plan occurs as a direct consequence of 
the HTA advice.57 Beyond gaining a reimbursement agency’s 
insight on the strategic development plan and optimizing the 
evidence generation program accordingly, other more subtle 
factors for the manufacturers to apply could be an expectation 
of a later-facilitated technology appraisal, the collection of 
an informal endorsement on the evidence program, or of the 
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agency perspective on the development program, regardless 
of the intention to access that specific market.36,57
In terms of interactions between different players, models 
are still different in terms of the importance played by early 
interaction and postlaunch risk-sharing agreements, the level 
of transparency of this interaction, and the object of this 
interaction. Our research focused on two case studies that 
share a rather good level of transparency in the way premar-
keting advice is managed, but follow different appraisal and 
recommendation rules. As already mentioned, heterogeneity 
of HTA practices around Europe increases the complexity of 
the market access environment and future European projects’ 
collaboration on early dialogue, such as the Shaping European 
Early Dialogue program, are needed to address this issue.41
Overall, there are concrete signals that Market Access 
departments and activities are gaining importance in the 
pharmaceutical companies, but there is still a lack of evidence 
and reporting on how the increasing relevance of HTA has 
reshaped the way clinical development is designed and man-
aged. This may strongly depend on the importance played by 
market access issues compared with marketing approval and 
market access barriers: the more these barriers are diffused in 
countries where market potentials are high and growing, the 
more companies are expected to design clinical development 
considering market issues also.58
As our objective was to illustrate HTA activities poten-
tially influencing the drug development path of pharmaceu-
ticals, we performed a review of information available on 
institutional websites or published documents. An interesting 
extension of the present work would be the collection of 
primary data and insights from manufacturers to measure the 
actual extent of the impact such HTA activities are having 
on their business. In conclusion, further research on how 
HTA and regulatory authorities’ practices develop to manage 
evolving knowledge and on how manufacturers respond with 
an efficient and adequate drug development program, both 
with the ultimate interest of patients’ benefit, is welcome.
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